An interventional study of Blood and tissue collection for immunological studies, advanced imaging. and neoadjuvant Therapy in Soft Tissue Sarcoma Adult, sponsored by University Hospital Tuebingen. Active, not recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by University Hospital Tuebingen · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 103 studies in Sarcoma with a site in Germany — 21 open to participants now, 30 under way, 3 of them phase 3. Sarcoma · Germany.
Among the 103 studies in Sarcoma with a site in Germany, this one is the 66th largest by planned enrollment of the 83 interventional ones that give a count, is one of 6 that started in 2021, is one of 12 with no phase, reaches primary completion later than 23 of the 29 other live ones, and was the 92nd registered.
1,610 studies on the registry are indexed under Sarcoma; 367 are open to participants now.
Browse Sarcoma studies →21 of the 103 studies in Sarcoma with a site in Germany are open now. Recruiting first, the newest first:
Universität Duisburg-Essen · Sites in Germany
Ages 15+
Technical University of Munich · Sites in Germany
Technische Universität Dresden · Sites in Germany
Ages 18+
Novartis Pharmaceuticals · Sites in Germany, United States, Canada and 4 more countries
Ages 18+
Adcendo ApS · Sites in Germany, United States, Belgium and 2 more countries
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 302 Sarcoma studies recruiting now, 192 (64%) set no upper age limit and 83 (27%) stop at 75 or younger; 94 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
103 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 44 · Phase 3 19
First in 1995; this study’s year is marked. 6 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 41 across 1,255 interventional studies indexed under Sarcoma.
Median enrollment 103 across the 83 interventional studies, 130 across the 19 observational. Of the 69 that completed or were terminated, 21 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
41 of 103 have an industry lead sponsor. The 10 most frequent:
University Hospital Tuebingen is the lead sponsor of 492 studies on the registry; 110 are open to participants now.
University Hospital Tuebingen has 6 studies filed under Sarcoma — fewer than ten, so there is no comparison to draw.
5 of the studies in Sarcoma with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07939139Technical University of MunichShadow-Mode Evaluation of an AI Assistant for Multidisciplinary Tumor Boards | 2027-01-31 |
| NCT05492682Valo Therapeutics OySTART: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer | 2027-04-30 |
| NCT02650401Hoffmann-La RocheStudy Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options | 2027-06-30 |
| NCT07148193Technische Universität DresdenQuality of Life and Medical Care of Long-term Sarcoma Survivors in Germany (PROSa+) | 2027-09 |
| NCT06743958Technical University of MunichPrehabilitation in Childhood Soft Tissue or Bone Sarcomas | 2027-10-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 103 studies in Sarcoma with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
"Blood and Tissue Extraction for Immunological Examinations During Neoadjuvant Therapy of Soft Tissue Sarcoma" is a prospective study with additional translational research using preoperative and postoperative tissue, blood sampling and advanced imaging.
All patients (> 18 Years) with histologically confirmed high-risk soft tissue sarcoma eligible for neoadjuvant multimodal therapy (including radiotherapy +/- concomitant and sequential chemotherapy +/- hyperthermia as well as surgery) are screened for the study. Neoadjuvant therapy consists of 50-50.4 Gy in 25-28 fractions. Additional concomitant or sequential chemotherapy may be applied in selected cases (young patients, high-grade tumors). Additional hyperthermia concomitant to neoadjuvant radiotherapy is applied in selected cases if not contraindicated.
Preoperative tissue sampling to generate primary tumor cell lines in additional translational research is performed in each patient with a lesion suspect for soft tissue sarcoma and eligible for multimodal therapy. Primary cell lines are analyzed biologically (growth pattern, radioresistance, migration, molecular markers RT-PCR, immunological properties such as immunogenic cell death, lysis by cellular immunotherapies such as CAR-NK cells. Postoperative tumor tissues are additionally analyzed for immune cell mapping using complex immunohistochemistry. Biopsy and resection should include proteome analysis and DNA sequencing (only of the tumor tissue, not normal tissue).
Additional immunological monitoring (including cellular immune status, serum marker e.g. cell free DNA, HMGB1) is performed using blood sampling with in total 4 blood controls (25 ml each, before neoadjuvant radiotherapy, during the second and last week of radiotherapy as well as before surgery). In patients treated with concomitant MR-guided hyperthermia, weekly MR-imagine is performed.
Follow-up is carried out as part of the oncological controls over 5 years. The overall study is planned over a period of 5 years (interventional part), additional 5 years follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood and tissue collection for immunological studies under neoadjuvant Therapy of soft tissue sarcomas. Prospective data collection and translational accompanying research on standard therapy. Use of tissue, blood samples and advanced imaging.
Other: Blood and tissue collection for immunological studies, advanced imaging. · Other: neoadjuvant Therapy
Blood and tissue collection for immunological studies under neoadjuvant Therapy of soft tissue sarcomas. Prospective data collection and translational accompanying research on standard therapy. Use of tissue, blood samples and advanced imaging.
neoadjuvant Therapy
Description of the cellular immune status via flow-cytometrie from collected blood samples
Blood samples are taken on the days of simulation-CT, first and third week of the radiation therapy, as well as before surgery.
Time frame: 5 years of recruitment, 5 years follow-up
Description of the cellular immune status on tissue samples ussing komplex immunohistochemie
Tissue samples are taken as incisional biopsie as well as in the tumor tissue after the surgery
Time frame: 5 years of recruitment, 5 years follow-up
Measurement of the cellular free DNA from collected blood samples
Blood samples are taken on the days of simulation-CT, first and third week of the radiation therapy, as well as before surgery.
Time frame: 5 years of recruitment, 5 years follow-up
Measurement of HMGB1 from collected blood samples
Blood samples are taken on the days of simulation-CT, first and third week of the radiation therapy, as well as before surgery.
Time frame: 5 years of recruitment, 5 years follow-up
Evaluation of morphological tumor characteristics (size, diffusion) with weekly MRIs
Weekly MRIs during neoadjuvant radiation therapy
Time frame: 5 years of recruitment, 5 years follow-up
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2021 (actual). Primary completion is estimated for Dec 2028, 89 months after the start.
Of 145 non-industry interventional studies with no phase under Sarcoma, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 120. This study's planned 89 months is above that.
Counting every sponsor, half of 148 studies reached it within 59 months; a quarter within 34 and three quarters within 120.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Jul 2026 → Dec 2028 and completion Jul 2031 → Dec 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital Tuebingen →